Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients

Veronica Marin1, Kyle Poulsen2, Gemma Odena3

  • 1Italian Liver Foundation, AREA science Park, Trieste, Italy.

Journal of Hepatology
|June 26, 2017
PubMed
Abstract

Insights

Hepatocytes, not immune cells, produce macrophage migration inhibitory factor (MIF) in response to alcohol, driving alcoholic liver disease (ALD) progression. Inhibiting MIF may offer a new therapeutic strategy for ALD.

Area of Science:

  • Hepatology
  • Immunology
  • Molecular Biology

Background:

  • Macrophage migration inhibitory factor (MIF) is a cytokine involved in inflammatory responses.
  • The cellular source and role of MIF in alcoholic liver disease (ALD) are not fully understood.
  • This study investigates hepatocytes as a potential source of MIF in ALD.

Purpose of the Study:

  • To determine if hepatocytes are a significant source of MIF in alcoholic liver disease.
  • To elucidate the role of MIF produced by non-myeloid cells in the pathogenesis of ALD.
  • To assess the correlation between MIF levels and disease severity in patients with alcoholic hepatitis.

Main Methods:

  • Measured MIF release from hepatocytes (HuH7) and macrophages (THP-1) exposed to ethanol.
  • Utilized bone marrow chimeras (Mif-/-→WT and WT→Mif-/-) to assess ethanol-induced liver injury.
  • Analyzed MIF in patient serum and liver biopsies from individuals with alcoholic hepatitis.

Main Results:

  • Hepatocytes, but not macrophages, released MIF when treated with ethanol.
  • Mice with MIF-producing non-myeloid cells showed increased liver injury markers after ethanol feeding.
  • MIF was predominantly localized to hepatocytes in human liver biopsies, and suprahepatic MIF levels correlated with disease severity and mortality risk.

Conclusions:

  • Hepatocyte-derived MIF plays a critical role in the development of alcoholic liver disease in mice.
  • These findings suggest that MIF contributes to liver injury in patients with alcoholic hepatitis.
  • Targeting MIF production could be a potential therapeutic approach for ALD.

Related Concept Videos